Bimagrumab: A Literature Course on What the Studies Report

Bimagrumab, also referred to in the literature by the development code BYM338, is an investigational human monoclonal antibody directed against activin type II receptors (ActRII). A 2024 review described it as a human monoclonal antibody against activin type II receptors under investigation for the treatment of obesity (PMID 39385353). This course walks through six modules: what the molecule is, how the literature describes its mechanism, what individual studies reported, what adverse events were published, what pharmacokinetic data exist, and what its regulatory status is. Each module closes with the limits of that evidence.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health or medication question. It describes what researchers did and what they reported, and it does not describe or suggest use by any individual.

Module 1: What Bimagrumab Is and How It Has Been Studied

Definition and class

Bimagrumab is classified in the published literature as a fully human monoclonal antibody, not as a short synthetic peptide. The 2024 review of the molecule characterised it as a human monoclonal antibody that binds activin type II receptors and is investigational for obesity (PMID 39385353). A 2025 narrative review grouped its investigational applications across inclusion body myositis, sarcopenia and medication-induced lean body mass loss (PMID 41248895). Because it is an antibody rather than a peptide, its size, manufacture and handling differ substantially from the small synthetic peptides that are often discussed alongside it.

Origin and forms

The molecule appears in the pharmacology literature under both its generic name and the code BYM338, as in a 2023 pooled analysis titled "Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)" (PMID 36527600). Trials that reported a route of administration used intravenous infusion; the phase 2 study in adults with type 2 diabetes and obesity administered bimagrumab intravenously at 10 mg/kg up to a maximum of 1200 mg every 4 weeks for 48 weeks (PMID 33439265). No approved bimagrumab product exists in any dosage form.

How it has been studied

Published clinical research has spanned four broad populations: sporadic inclusion body myositis (sIBM), age-related sarcopenia, obesity with type 2 diabetes, and obesity treated alongside a GLP-1 receptor agonist. A 2024 systematic review and meta-analysis pooled trials that measured body composition outcomes with bimagrumab (PMID 39251484), and a 2019 review summarised the sIBM literature alongside alemtuzumab (PMID 30238817).

Limits of the evidence in Module 1

The available studies are phase 2 in scale, use different comparators and durations, and were conducted in selected populations. No long-term phase 3 outcome trial appears in the verified literature reviewed here, and descriptive reviews are not themselves sources of new efficacy or safety data.

Module 2: Mechanism as Described in the Literature

Reviews describe bimagrumab as binding to activin type II receptors (ActRIIA and ActRIIB) and thereby blocking the binding of ligands such as myostatin and activins, which interrupts downstream signalling that normally restrains skeletal muscle growth; the 2024 review presented this receptor-blockade mechanism as the rationale for its investigation in obesity (PMID 39385353). The 2025 review framed the same pathway inhibition as the basis for testing the antibody in conditions marked by muscle loss, including sarcopenia and medication-induced reductions in lean body mass (PMID 41248895).

A second element of the described mechanism is the effect on adipose tissue. The 2024 systematic review and meta-analysis reported that trials of bimagrumab measured both increases in lean mass and decreases in fat mass as body composition endpoints (PMID 39251484), and the phase 2 trial in adults with type 2 diabetes and obesity was designed with total body fat mass as its primary endpoint (PMID 33439265). A 2026 report examined the consequences of chronic inhibition of the myostatin–activin pathway with bimagrumab for cardiac structure and function in healthy older adults (PMID 41873146), reflecting that the targeted pathway is expressed beyond skeletal muscle.

Limits of the evidence in Module 2

Mechanistic accounts in these papers are largely narrative and are inferred from receptor pharmacology plus observed body composition changes. The verified literature summarised here does not establish which tissue-level pathways account for the reported fat mass changes, nor does it resolve how much of any observed effect reflects muscle signalling versus adipose signalling.

Module 3: Reported Outcomes by Study

Obesity with type 2 diabetes

In the phase 2 randomised clinical trial of bimagrumab versus placebo in adults with type 2 diabetes and obesity, researchers reported that intravenous bimagrumab at 10 mg/kg (maximum 1200 mg) every 4 weeks over 48 weeks was associated with a roughly 20% reduction in total body fat mass compared with a minimal change on placebo, alongside an increase in lean mass of approximately 3.6% and a greater reduction in HbA1c than placebo (PMID 33439265). The authors of that study described the findings as warranting further investigation rather than as establishing a treatment.

Obesity with a GLP-1 receptor agonist

A 2026 randomised phase 2 trial tested bimagrumab and semaglutide alone or in combination in obesity, and the researchers reported that the combination produced greater reductions in fat mass than semaglutide alone while attenuating the loss of lean mass seen with semaglutide monotherapy (PMID 41772149). The 2025 review placed this line of research within the broader question of medication-induced lean body mass loss (PMID 41248895).

Sarcopenia

A 2017 phase 2 proof-of-concept study in older adults with sarcopenia reported that a single intravenous dose of bimagrumab increased thigh muscle volume and lean body mass and decreased fat mass relative to placebo, with mobility measures improving in some participants (PMID 28653345). A larger 2020 randomised trial compared bimagrumab with optimised standard of care in community-dwelling older adults with sarcopenia, and the researchers reported gains in lean mass and reductions in fat mass without a clear additional benefit on physical function beyond that seen with optimised standard of care alone (PMID 33074327).

Sporadic inclusion body myositis

The long-term extension of the RESILIENT trial reported that bimagrumab increased lean body mass and thigh muscle volume in participants with sporadic inclusion body myositis but did not improve 6-minute walking distance compared with placebo (PMID 33597289). The 2019 review of sIBM pharmacotherapy discussed bimagrumab alongside alemtuzumab and noted the absence of established disease-modifying therapy in that condition (PMID 30238817).

Pooled body composition analysis

The 2024 systematic review and meta-analysis of bimagrumab and body composition reported a consistent direction of effect across included trials, with lean mass increasing and fat mass decreasing (PMID 39251484).

Limits of the evidence in Module 3

Across these studies, changes in imaging or body composition measures did not consistently translate into changes in function or clinical outcomes, most clearly in sporadic inclusion body myositis (PMID 33597289) and in sarcopenia compared with optimised standard of care (PMID 33074327). Trial durations were measured in months to a small number of years, comparators differed, and none of this constitutes a promise of benefit for any individual.

Module 4: Bimagrumab Side Effects: What Studies Report

Adverse events in the published record cluster around muscle and gastrointestinal symptoms. The phase 2 trial in adults with type 2 diabetes and obesity reported that muscle spasms, diarrhoea and acne occurred more often with bimagrumab than with placebo, and the authors described most events as mild (PMID 33439265). The 2026 phase 2 trial of bimagrumab and semaglutide also reported muscle spasms and gastrointestinal events among the adverse events recorded during treatment (PMID 41772149).

In neuromuscular disease, the long-term extension of RESILIENT reported adverse events including muscle spasms, diarrhoea and falls during extended bimagrumab exposure in participants with sporadic inclusion body myositis, a population already at high risk of falls (PMID 33597289). The sarcopenia trial comparing bimagrumab with optimised standard of care reported muscle spasms and diarrhoea as more frequent in the bimagrumab groups (PMID 33074327), and the earlier proof-of-concept study reported that a single intravenous dose was generally tolerated with muscle cramps and spasms among the events noted (PMID 28653345).

Cardiac outcomes were examined specifically: a 2026 study evaluated cardiac structure and function during chronic inhibition of the myostatin–activin pathway with bimagrumab in healthy older adults and was published under the framing of cardiac safety (PMID 41873146). Reviews summarising the programme also discussed tolerability as a consideration in further development (PMID 39385353, PMID 41248895).

Limits of the evidence in Module 4

Adverse-event data come from trials with limited sample sizes and durations, so uncommon or delayed events may not have been detected. Populations differed markedly — healthy older adults, adults with obesity, and people with a progressive myopathy — so event rates from one study do not transfer to another. No post-marketing surveillance exists for a compound with no marketing authorisation.

Module 5: Pharmacokinetics Where Data Exist

The most detailed pharmacokinetic source in this literature is the 2023 pooled analysis of bimagrumab (BYM338), which characterised the antibody's pharmacokinetics and related exposure to pharmacodynamic effects on body composition (PMID 36527600). Consistent with a monoclonal antibody directed at a cell-surface receptor, that analysis described disposition influenced by target binding rather than the simple linear kinetics typical of small molecules (PMID 36527600).

Clinically, exposure was achieved through intermittent intravenous infusion rather than daily administration: the phase 2 obesity and type 2 diabetes trial used 10 mg/kg up to 1200 mg every 4 weeks across 48 weeks (PMID 33439265), while the sarcopenia proof-of-concept study assessed outcomes after a single intravenous dose, with muscle and fat mass changes still measurable weeks later (PMID 28653345).

Limits of the evidence in Module 5

Pharmacokinetic modelling was based on pooled clinical datasets in adults and does not describe paediatric populations, pregnancy, or people with significant organ impairment. Because bimagrumab is a large protein, no oral or self-administered formulation pharmacokinetics appear in the verified literature summarised here.

Module 6: Regulatory Status

Stated factually: bimagrumab has no approved product on the market. It is described in the peer-reviewed literature as an investigational human monoclonal antibody, including in the 2024 review of its development for obesity (PMID 39385353) and in the 2025 review of its investigational applications across inclusion body myositis, sarcopenia and medication-induced lean body mass loss (PMID 41248895). Studies conducted to date were clinical trials under investigational frameworks, including the phase 2 trial in type 2 diabetes and obesity (PMID 33439265) and the phase 2 trial with semaglutide (PMID 41772149).

Antibodies such as bimagrumab are biological products. In the United States, biologics are licensed under the Public Health Service Act rather than approved as small-molecule drugs, and they fall outside the categories that pharmacies typically compound from bulk substances; an unapproved investigational biologic has no lawful pathway to pharmacy compounding. Laboratory reagents sold as "research use only" are labelled for in vitro or laboratory research and not for administration to humans. This is general regulatory information, not legal advice; rules differ by country and can change.

Limits of the evidence in Module 6

Regulatory status is time-sensitive and independent of scientific findings: positive body composition results in phase 2 trials do not imply approval, and the published record reviewed here contains no statement of marketing authorisation in any jurisdiction.

What the Studies Did Not Test

• Long-term outcomes. The verified trials measured body composition, laboratory and functional endpoints over months; none reported cardiovascular event rates, mortality or decade-scale safety.
• Function as a primary win. The sIBM extension reported muscle mass gains without improvement in 6-minute walking distance (PMID 33597289), and the sarcopenia comparison against optimised standard of care did not show a clear added functional advantage (PMID 33074327).
• Non-intravenous administration. The pharmacokinetic literature reviewed here addresses intravenous exposure (PMID 36527600).
• Healthy people seeking body composition change. Enrolment in the reported trials was defined by diagnosed conditions such as obesity with type 2 diabetes (PMID 33439265) or sarcopenia (PMID 28653345), except for the cardiac safety evaluation in healthy older adults (PMID 41873146).
• Interactions and special populations. Pregnancy, paediatric use, and combination with agents other than semaglutide (PMID 41772149) were not addressed in the literature summarised here.

The pooled analysis of body composition effects concluded that further research was needed to clarify the clinical meaning of the observed changes (PMID 39251484). Readers with questions about any compound discussed here should consult a licensed physician.

References

• Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial (JAMA Network Open, 2021)
• Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338) (Clinical Pharmacokinetics, 2023)
• Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial (Nature Medicine, 2026)
• Effect of Bimagrumab on body composition: a systematic review and meta-analysis (Aging Clinical and Experimental Research, 2024)
• Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity (Journal of Basic and Clinical Physiology and Pharmacology, 2024)
• Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT (Neurology, 2021)
• Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial (JAMA Network Open, 2020)
• Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study (Journal of the American Geriatrics Society, 2017)
• Bimagrumab: Novel Medical Therapy for Inclusion Body Myositis, Sarcopenia, and Medication-Induced Lean Body Mass Loss (Cardiology in Review, 2025)
• A review on the treatment of sporadic inclusion body myositis with Bimagrumab and Alemtuzumab (International Journal of Neuroscience, 2019)
• Cardiac safety of chronic inhibition of the myostatin-activin pathway with bimagrumab in healthy older adults (Journal of Clinical Endocrinology and Metabolism, 2026)